Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.

Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.

Abstract: Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.

Abstract: Embodiments of the invention are directed to improved discrimination of protective (anti-atherogenic) HDL from atherogenic or non-protective (NP) HDL. The methods, systems and computer program products determine protective high density lipoprotein particle (HDL-P) numbers. The methods include obtaining concentration measurements of at least twenty subpopulations of HDL-P subclasses in a blood plasma or serum sample and calculating a protective HDL-P number using (i) a defined subset of the obtained HDL-P concentration measurements or (ii) a zero or defined weighting factor below 1 for HDL-P concentration measurements for HDL subclasses associated with particle sizes above about 11 nm.

Abstract: Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and/or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.

Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.

Abstract: Methods, computer program products and apparatus automate clinical NMR in vitro diagnostic analyzers. The clinical analyzer can automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites; and at least one remote control system in communication with one or a plurality of clinical NMR analyzers, the at least one remote system configured to monitor selected local operating parameters associated with a respective clinical NMR analyzer.

Abstract: Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated LDL particle risk number and/or a mathematical model of risk associated with LDL particles that adjusts concentrations of at least one of small and large LDL particle measurements to reflect predicted CHD risk.

Abstract: Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and/or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.

Abstract: Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and/or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL/RHDL.

Abstract: Methods for assessing a patient's risk of having or developing coronary heart disease based on lipoprotein measurements measure and identify values for lipoprotein subclass constituents and analyze according to predetermined test criteria to identify when there is an increased and/or decreased risk of having and/or developing coronary heart disease associated wit the measured lipoprotein subclass constituent values.

Abstract: A method of screening a subject for the presence of lipoprotein X includes the steps of: producing a measured lipid signal lineshape of an NMR spectrum of a blood plasma or serum sample obtained from a subject; generating a calculated lineshape for the sample, the calculated lineshape being based on derived concentrations of lipoprotein components potentially present in the sample, the derived concentration of each of the lipoprotein components being the function of a reference spectrum for that component and a calculated reference coefficient, wherein one of the lipoprotein components for which a concentration is calculated is lipoprotein X; and determining the degree of correlation between the calculated lineshape of the sample and the measured lineshape spectrum of the sample.

Abstract: Methods for assessing a patient's risk of having or developing coronary heart disease based on lipoprotein measurements include: (a) generating an NMR spectroscopic signal of a blood plasma or serum sample of a patient; (b) measuring the values of a plurality of selected lipoprotein subclass constituents in the sample; (c) analyzing the measured values of the lipoprotein subclass constituents according to predetermined test criteria to identify when there is an increased and/or decreased risk of having and/or developing coronary heart disease associated with the measured lipoprotein subclass constituent values; (d) outputting the measured lipoprotein subclass values onto a report; (e) providing a plurality of risk analysis portions that depicts the identified risk of the measured lipoprotein subclass values from the predetermined test criteria analysis, a respective one for each measured lipoprotein subclass value, wherein each risk analysis portion defines a plurality of risk segments that are associated wit

Abstract: A method for analyzing a patient's risk of coronary heart disease by determining the presence of NMR-derived or based lipoprotein constituent value abnormalities includes determining the presence of atherogenic dyslipidemia based on the existence of a clustering of lipoprotein constituent abnormalities as defined by predetermined test criteria. Computer program products and automatically produced reports for presenting NMR-derived lipoprotein risk assessment based on patient-specific lipoprotein subclass results present the measurement results adjacent to a segmented reference risk analysis portion. The actual measured results are visually aligned and enhanced within the risk analysis portion to provide easy reference and understanding of the results relative to a risk of developing coronary heart disease.

Abstract: A method of screening a subject for the presence of lipoprotein X includes the steps of: producing a measured lipid signal lineshape of an NMR spectrum of a blood plasma or serum sample obtained from a subject; generating a calculated lineshape for the sample, the calculated lineshape being based on derived concentrations of lipoprotein components potentially present in the sample, the derived concentration of each of the lipoprotein components being the function of a reference spectrum for that component and a calculated reference coefficient, wherein one of the lipoprotein components for which a concentration is calculated is lipoprotein X; and determining the degree of correlation between the calculated lineshape of the sample and the measured lineshape spectrum of the sample.

Abstract: Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes.

Abstract: A method for analyzing a patient's risk of coronary heart disease by determining the presence of NMR-derived or based lipoprotein constituent value abnormalities includes determining the presence of atherogenic dyslipidemia based on the existence of a clustering of lipoprotein constituent abnormalities as defined by predetermined test criteria. Computer program products and automatically produced reports for presenting NMR-derived lipoprotein risk assessment based on patient-specific lipoprotein subclass results present the measurement results adjacent to a segmented reference risk analysis portion. The actual measured results are visually aligned and enhanced within the risk analysis portion to provide easy reference and understanding of the results relative to a risk of developing coronary heart disease.

Abstract: A method and apparatus for analyzing blood plasma or serum to determine the concentrations of its lipoprotein constituents includes obtaining the NMR chemical shift spectrum of a sample, Stored reference NMR spectra of the constituent subclasses of major lipoprotein classes are added together to form a lineshape that best fits the measured blood plasma NMR spectrum, and from this, the concentration of each lipoprotein constituent in the blood plasma or serum is determined.

Abstract: A method and apparatus for analyzing blood plasma to determine the concentration of its lipoprotein constituents, VLDL, LDL, HDL and proteins includes obtaining the NMR chemical shift spectrum of a sample. Stored reference NMR spectra of the lipoprotein constituents are added together to form a lineshape that best fits the measured blood plasma NMR spectrum, and from this, the concentration of each lipoprotein constituent in the blood plasma is determined.